As part of the collaboration, AAX Biotech will apply Seqitope to characterize Vascurie’s antibody candidates against CD93, a novel drug target in neuro-oncology. Seqitope combines amino acid-level epitope insights with the ability to process large numbers of antibodies in parallel, enabling rapid and data-rich decision-making during therapeutic development.

To address the increasing demand for high-throughput analyses that accelerate drug discovery, AAX Biotech recently installed an advanced automation robot designed to enable large-scale Seqitope workflows, while significantly increasing speed and scalability. The collaboration with Vascurie will be executed as a high-throughput project, fully utilizing these expanded capabilities.

“The ability to generate high-resolution epitope data at true high throughput represents a significant advance for antibody discovery and development,” says Daniel X. Johansson, CEO and CSO of AAX Biotech. “With Seqitope and our new robotic platform, we can now characterize up to 100 antibodies in parallel, providing Vascurie with rapid, high-quality insights to support their neuro-oncology programs.”

“This collaboration strategically accelerates our initiative to develop monoclonal antibodies targeting CD93. By enabling multiplex parallel analysis of our proprietary molecules, this comprehensive approach will rapidly generate critical insights into the molecular pharmacology of our lead candidate, VDL-309, and other antibodies with distinct biomedical properties,” says Jonas Ekblom, CEO of Vascurie. “This dataset generated together with AAX Biotech will allow Vascurie to de-risk the development and optimize the selection of backup compounds.”